Position of COMT inhibition in the treatment of Parkinson's disease

被引：0
|
作者：
Gordin, AR [1 ]
Kaakkola, T
Teräväinen, H
机构：
[1] Orion Pharma, Res Ctr, Espoo, Finland
[2] Univ Helsinki, Dept Neurol, Helsinki, Finland
来源：
PARKINSON'S DISEASE | 2003年 / 91卷
关键词：
D O I：
暂无
中图分类号：
Q3 [遗传学];
学科分类号：
071007 ; 090102 ;
摘要：
引用
收藏
页码：237 / 250
页数：14
相关论文
共 50 条
  • [31] Long-term benefit of COMT inhibition in Parkinson's disease patients switched from tolcapone to entacapone
    Bellino, A
    Antonini, A
    Sacilotto, G
    Meucci, N
    Pezzoli, G
    NEUROLOGY, 2000, 54 (07) : A279 - A279
  • [32] COMT-inhibition increases serum levels of dihydroxyphenylacetic acid (DOPAC) in patients with advanced Parkinson's disease
    M. Oechsner
    C. Buhmann
    J. Strauss
    H. J. Stuerenburg
    Journal of Neural Transmission, 2002, 109 : 69 - 75
  • [33] COMT-inhibition increases serum levels of dihydroxyphenylacetic acid (DOPAC) in patients with advanced Parkinson's disease
    Oechsner, M
    Buhmann, C
    Strauss, J
    Stuerenburg, HJ
    JOURNAL OF NEURAL TRANSMISSION, 2002, 109 (01) : 69 - 75
  • [34] DFT and QSAR study of Catechol-O-methyltransferase (COMT) as inhibitors for Parkinson's disease treatment
    Sherif, Salma
    Sameh, Ahmed
    Salah, Sohaila Mohammed
    Omar, Amina
    Elhaes, Hanan
    Ibrahim, Asmaa
    Refaat, Ahmed
    Ibrahim, Medhat A.
    OPTICAL AND QUANTUM ELECTRONICS, 2024, 56 (04)
  • [35] The place of COMT inhibitors in the armamentarium of drugs for the treatment of Parkinson's disease - Discussion - Dr. Schapira
    Schapira
    Fahn
    Olanow
    Dingemanse
    Waters
    Korczyn
    Gordin
    Koller
    Obeso
    Jenner
    Rascol
    NEUROLOGY, 2000, 55 (11) : S69 - S71
  • [36] DFT and QSAR study of Catechol-O-methyltransferase (COMT) as inhibitors for Parkinson’s disease treatment
    Salma Sherif
    Ahmed Sameh
    Sohaila Mohammed Salah
    Amina Omar
    Hanan Elhaes
    Asmaa Ibrahim
    Ahmed Refaat
    Medhat A. Ibrahim
    Optical and Quantum Electronics, 56
  • [37] The relationship between COMT genotype and the clinical effectiveness of tolcapone, a COMT inhibitor, in patients with Parkinson's disease
    Chong, DJ
    Suchowersky, O
    Szumlanski, C
    Weinshilboum, RM
    Brant, R
    Campbell, NRC
    CLINICAL NEUROPHARMACOLOGY, 2000, 23 (03) : 143 - 148
  • [38] COMT genotype and effectiveness of entacapone in patients with fluctuating Parkinson's disease
    Lee, MS
    Kim, HS
    Cho, EK
    Lim, JH
    Rinne, JO
    NEUROLOGY, 2002, 58 (04) : 564 - 567
  • [39] Effect of COMT-inhibitor in the clinical progression of Parkinson's disease
    Song, I. U.
    Lee, K. S.
    Chung, Y. A.
    MOVEMENT DISORDERS, 2018, 33 : S120 - S120
  • [40] Catechol-O-methyltransferase (COMT) inhibitors in Parkinson's disease
    Waters, C
    JOURNAL OF THE AMERICAN GERIATRICS SOCIETY, 2000, 48 (06) : 692 - 698
12345